# COSI (NCT04217278)

> A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

No report yet. It can be ordered.

- Drugs tested: CPX-351; TBF; Mini-TBF
- Indication: AML or high-risk MDS undergoing allogeneic SCT

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04217278
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Birmingham
- Conditions: Acute Myeloid Leukaemia; High-risk Myelodysplastic Syndrome
- Interventions: Vyxeos; Fludarabine; Busulphan; Thiotepa; Cytarabine
- Enrollment: 333
- Primary outcome: Overall survival (all randomisations)

## Indexed commentary on COSI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 2 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cosi-nct04217278